Dianthus Therapeutics (DNTH) Invested Capital: 2017-2025
Historic Invested Capital for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $546.5 million.
- Dianthus Therapeutics' Invested Capital rose 61.72% to $546.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.5 million, marking a year-over-year increase of 61.72%. This contributed to the annual value of $352.5 million for FY2024, which is 108.73% up from last year.
- As of Q3 2025, Dianthus Therapeutics' Invested Capital stood at $546.5 million, which was up 80.30% from $303.1 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Invested Capital ranged from a high of $546.5 million in Q3 2025 and a low of -$61.5 million during Q2 2023.
- In the last 3 years, Dianthus Therapeutics' Invested Capital had a median value of $328.6 million in 2025 and averaged $257.7 million.
- Its Invested Capital has fluctuated over the past 5 years, first crashed by 145.30% in 2023, then surged by 833.35% in 2024.
- Quarterly analysis of 4 years shows Dianthus Therapeutics' Invested Capital stood at -$44.4 million in 2022, then spiked by 480.61% to $168.9 million in 2023, then spiked by 108.73% to $352.5 million in 2024, then skyrocketed by 61.72% to $546.5 million in 2025.
- Its Invested Capital stands at $546.5 million for Q3 2025, versus $303.1 million for Q2 2025 and $328.6 million for Q1 2025.